TTP399, a novel glucokinase activator shows statistically significant reduction in HbA1c without increases in ketones or hypoglycemia HIGH POINT, N.C. --(BUSINESS WIRE)--Jun. 6, 2019-- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced positive results from the primary analysis of Part 1 of the
HIGH POINT, N.C. --(BUSINESS WIRE)--May 1, 2019-- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the first quarter that ended March 31, 2019 , and provided an update on recent achievements and upcoming events. “We continue to make significant progress with our operational
Presentation of Results for Subgroup of Patients with Mild Alzheimer’s Disease and Type 2 Diabetes in the STEADFAST Study HIGH POINT, N.C. --(BUSINESS WIRE)--Mar. 28, 2019-- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of
Proceeds Will Fund Start-Up Activities for Current and Future Clinical Trials HIGH POINT, N.C. --(BUSINESS WIRE)--Mar. 18, 2019-- vTv Therapeutics Inc. (Nasdaq:VTVT) (the “Company”) today announced that it has entered into a definitive agreement with certain institutional investors for the purchase
HIGH POINT, N.C. --(BUSINESS WIRE)--Feb. 27, 2019-- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the fourth quarter and year that ended December 31, 2018 , and provided an update on recent achievements and upcoming events. “We are excited about the therapeutic potential
Results Found TTP399 Demonstrated a Statistically Significant Improvement in HbA1c Compared to Placebo without Hypoglycemia or Hyperlipidemia HIGH POINT, N.C. --(BUSINESS WIRE)--Jan. 16, 2019-- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced the publication of a paper in Science Translational